Biotech Values

[DewDiligence]

Keytruda fails phase-3 in CRPC:

https://www.businesswire.com/news/home/20220803005334/en

Merck…today announced that the Phase 3 KEYNOTE-921 trial evaluating KEYTRUDA in combination with chemotherapy (docetaxel) compared to chemotherapy alone did not meet its dual primary endpoints of overall survival (OS) and radiographic progression-free survival (rPFS) for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC). In the study, there were modest trends toward an improvement in both OS and rPFS for patients who received KEYTRUDA plus chemotherapy compared with chemotherapy alone; however, these results did not meet statistical significance per the pre-specified statistical plan.

Keytruda will soon overtake Humira as the biggest-selling non-COVID drug from any company; however, it is not invincible.